Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)
Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last...
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025. The trial phases of...
What is Deramiocel? What Does CAP-1002 Do?
Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission...
Is Duchenne Gene Therapy a Suitable Treatment Despite its Immunogenic Class Effect?
Progressive muscle weakness and eventual mortality as a result of cardiomyopathy or respiratory complications are the hallmarks of Duchenne muscular dystrophy (DMD), a severe...
New Research on Duchenne Muscular Dystrophy Protein Interactions Lead to More Targeted Therapies
A pioneering discovery has shown the complicated relationships between dystrophin, a muscle stability protein, and its companion protein, dystrobrevin, opening new avenues for studying...